Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration
- Written by PR Newswire
- Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out discussions.
- Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025.
DAEJEON, South Korea, Feb. 22, 2023 /PRNewswire/ -- Alteogen...














